Ruxolitinib Alleviates Inflammation, Apoptosis, and Intestinal Barrier Leakage in Ulcerative Colitis via STAT3
Inflammatory Bowel Diseases · 01.08.2023 · 29 (8) · 1191-1201
DOI: 10.1093/ibd/izad007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 31.01.2023. Verfasst von Chunxiao Li und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Colitis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, Medical and Health Plan of Zhejiang.
Abstract (Originalsprache)
Background
Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disorder of the colonic mucosa with increasing prevalence and limited management. Ruxolitinib is a new anti- JAK/STAT3 biologic agent that has shown potential in protecting against colitis.
Methods
We first constructed an in vivo UC model and an in vitro colonic epithelial cell inflammation model. Ruxolitinib was administered via gavage in mice. After treatment, colon tissues, cells, and cell lysates were collected and prepared for histological evaluation, immunohistochemistry, immunofluorescence staining, quantitative reverse-transcriptase polymerase chain reaction, Western blotting, terminal deoxynucleotidyl transferase mediated dUTP nick end labeling staining, and cytokine analysis. STAT3 expression was silenced and overexpressed via small interfering RNA and overexpression plasmid transfection, respectively, and quantitative reverse-transcriptase polymerase chain reaction was used to examine the downstream effects.
Results
Ruxolitinib administration significantly alleviated colitis both in vivo and in vitro, as manifested by reduced body weight loss, shortened colon lengths, relieved disease activity (measured by the disease activity index), and prolonged survival. A mechanistic study showed that ruxolitinib attenuated nuclear factor kappa B–induced inflammation, reduced apoptosis, and ameliorated epithelial barrier leakage, and thereby reduced colitis activity in vivo. STAT3 knockdown partially reversed the protective effect of ruxolitinib against colitis, while STAT3 overexpression exaggerated the reductions in proinflammatory cytokine levels upon ruxolitinib treatment.
Conclusions
We demonstrate that ruxolitinib alleviates colitis by inhibiting nuclear factor kappa B–related inflammation and apoptosis in addition to restoring epithelial barrier function via STAT3, providing a new strategy for UC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
- Department of Gastroenterology, Ningbo First Hospital, Ningbo, China.
- Department of Hematology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
- Department of Gastroenterology, Ningbo Yinzhou No.2 Hospital, Ningbo, China.
- Department of Orthopedics, Hua Mei Hospital, University of Chinese Academy of Sciences (Ningbo No. 2 Hospital), Ningbo, China.
- Central Laboratory of the Medical Research Center, Ningbo First Hospital, Ningbo, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Medical and Health Plan of Zhejiang
- Ningbo Medical Science and Technology Program
Zitieren
APA
Li, C., Xu, Y., Gao, T., Zhang, S., Lin, Z., Gu, S., Fang, Y., Yuan, X., Yu, S., Jiang, Q., Lou, Z., Zhang, X., Zhang, J., Wu, Q., Gu, M., Ding, X., Sun, J., & Chen, Y. (2023). Ruxolitinib Alleviates Inflammation, Apoptosis, and Intestinal Barrier Leakage in Ulcerative Colitis via STAT3. Inflammatory Bowel Diseases, 29(8), 1191-1201. https://doi.org/10.1093/ibd/izad007
Vancouver
Li C, Xu Y, Gao T, Zhang S, Lin Z, Gu S, et al. Ruxolitinib Alleviates Inflammation, Apoptosis, and Intestinal Barrier Leakage in Ulcerative Colitis via STAT3. Inflammatory Bowel Diseases. 2023;29(8):1191-1201. doi:10.1093/ibd/izad007
BibTeX
@article{Li2023,
author = {Li, Chunxiao and Xu, Yu and Gao, Tengjiao and Zhang, Shunyao and Lin, Zhe and Gu, Shaobo and Fang, Yi and Yuan, Xin and Yu, Siyi and Jiang, Qi and Lou, Zhongze and Zhang, Xiuming and Zhang, Jie and Wu, Qiaoyan and Gu, Mengli and Ding, Xiaoyun and Sun, Jing and Chen, Yi},
title = {Ruxolitinib Alleviates Inflammation, Apoptosis, and Intestinal Barrier Leakage in Ulcerative Colitis via STAT3},
journal = {Inflammatory Bowel Diseases},
year = {2023},
volume = {29},
number = {8},
pages = {1191--1201},
doi = {10.1093/ibd/izad007}
}
EUVIMED